Dabur India Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Seasonal headwinds mask underlying momentum: Consolidated sales grew just 1.7% as unseasonal rain crushed the seasonal portfolio, but ex-seasonal growth was 7% and rural markets outperformed urban for the fifth straight quarter.
• Healthcare portfolio is being reshaped, not abandoned: Glucose fell ~30% on weather, but Chyawanprash grew 28%, Honitus surged 46%, and management exited three tail brands to sharpen focus on core franchises.
• Oral Care is the standout engine: The Red franchise grew 9%, herbal toothpaste outpaced non-herbal by 440 bps, and an anti-fluoride campaign helped push volume market share to an all-time high of 16.6%.
• Margins held despite gross margin pressure: Competitive intensity forced higher BTL spending that diluted Ind AS gross margins, but operating profit and PAT still grew ahead of topline, and management expects a significant full-year margin improvement.
• What to watch next quarter: Whether the promised double-digit Q2 growth materializes given an exceptionally wet July that has already pressured beverages, and whether the GTM restructuring delivers measurable distributor ROI gains.

Seasonal Portfolio & The Weather Overhang

• Rain crushed the summer playbook: Unseasonal rain and a very short summer hit beverages and glucose hard, with glucose declining ~30% and the overall seasonal portfolio dragging consolidated growth down to 1.7% from 7% ex-seasonal.
• July is already wet: Management flagged that July has been unprecedented in rainfall, beverages have not done well, and the full-year beverage segment may see only low single-digit growth.
• The base effect cuts both ways: Last year's same quarter had an inventory correction at the general trade level, creating a favourable base for Q2 FY26; management expects double-digit growth in the coming quarter, but that depends on how the monsoon plays out.
• Non-beverage verticals carry the load: The other two verticals are expected to grow double digits on the lower base, with both urban and rural demand showing market share gains.

Malhotra: "For the full year, we want our operating margin to only inch up significantly as compared to last year to this year."

Healthcare: Portfolio Reshaping, Not Stagnation

• The COVID-base question lingers: An analyst flagged that the Healthcare segment has not crossed its ~₹1,600 cr COVID-era peak; management attributed the gap to glucose seasonality and tail-brand exits, and did not directly address whether core categories have lost relevance with younger consumers.
• Glucose was a weather casualty, not a structural one: The 30% decline was driven by unfavourable weather cycling a 31% high base, and the impact was industry-wide, hitting Zydus as well. Excluding glucose, Healthcare grew ~2.7%.
• Chyawanprash is working: Grew around 30% on a contextual monsoon campaign; new formats now contribute over 20% of the business and are margin-accretive; market share gained 111 bps.
• Honey has lapped its headwinds: Grew ~11% after last year's market returns issue is now behind; premium variants like Sundarbans and organic are doing well; 46 bps market share gain.
• OTC delivered where demand appeared: Honitus grew 46% on monsoon-driven cough and cold incidence; Hot Sip, a new format, grew 95%; Health Juices maintained strong trajectory at 18%.
• Tail-cutting is complete: Exited Diapers, Tea, and Vita (₹8 cr combined) as part of a vision exercise to focus on core brands, which pushed back absolute Healthcare growth in the quarter.
• Four brands flagged for doubling down: Pudin Hara, Health Juices, Hajmola, and Shilajit are targeted to scale, with Hajmola alone aimed at ~₹550 cr; new contemporary formats are promised in the next few months.
• Lal Tail has a localized problem: A small player called AD Oil took share in UP and Bihar; management identified the issue and says it will be corrected.

Malhotra: "I don't think there is any long-term any concern. Yes, the new generation is using newer formats and when you see new generation, its 10% of the population on e-commerce and quick commerce that you see, which is 10% of the industry. That 10% should not make a perception in you that 90% of the market is following 10% and these categories are not doing well."

Oral Care: The Standout Engine

• Herbal is structurally outgrowing non-herbal: The herbal toothpaste category grew at 2x the non-herbal segment, a 440 bps gap, and Dabur outperformed the category to sustain market share gains.
• Red franchise leads, new launches follow: Red grew 9% secondary and 8% IGAAP; Meswak grew ~5%; the new Dabur herbal toothpaste is growing 30%.
• Anti-fluoride campaign is a real driver: The Amitabh Bachchan endorsement and anti-fluoride messaging are working across regions, pushing volume market share up 14 bps to an all-time high of 16.6%.
• Confidence is high for sustained momentum: Management expects to maintain the same firing rate as Q1 and is very confident on improving trajectory.

Gross Margins, Competitive Intensity & Ad Spend

• Ind AS gross margin dilution is a BTL story: Competitive intensity from Colgate and in Hair Oils forced higher BTL spending that got netted off the top line; IGAAP gross margins were flat, so the dilution is a reporting artifact, not a cost-of-goods problem.
• A&P spending is rising, just redirected: Overall A&P moved up ~5% ahead of topline, but money was shifted from ATL to BTL; management denied any one-off in the base and committed to continuously increasing advertising and promotion expenditure.
• Edible oil inflation is manageable: Projected at 7-8%, management expects to protect margins through fresh price increases and heightened saving initiatives, with a string of initiatives lined up.
• Full-year margin ambition is explicit: Operating margins are expected to move up significantly from last year to this year, with the year-end exit as the target.

Malhotra: "Because of the competitive intensity from Colgate and in Hair Oils, we had to give a lot of BTL which got netted off from the top line, and therefore, you see a gross margin dilution in the Ind AS number."

Distribution, Disclosure & The Vision Exercise

• GT inventory has normalized: Last year's inventory correction at the general trade level is done; current 21-22 days of inventory is considered optimal for the diversified portfolio and seasonality, and stockists are making good ROI.
• A GTM restructuring is underway: The exercise aims to improve distributor ROI, achieve price equilibrium, and increase span of control; inventory levels are expected to remain similar, and there is no intention of increasing the pipeline.
• Disclosure changes raised eyebrows: An analyst noted a significant change in disclosures versus historical practice; management said the Investor Presentation was streamlined based on benchmarking with industry peers to avoid competitive sensitivity, and committed to transparency and consistency going forward.
• The vision exercise identified seven big moves: Double down on core brands (60-70% of business, ₹700 cr+); extend Dabur Red into other benefit gaps; contemporize Dabur Amla; scale four Healthcare brands to ₹100 cr each and Hajmola to ~₹550 cr; execute the GTM restructuring; and scout for M&A in new-age Healthcare, HPC, and F&B brands that are premium and margin-accretive with a path to profitability within a couple of years.

Guidance & Commitments

Key Metrics